Cometriq for renal cell carcinoma – pro
Cometriq is a kinase inhibitor that’s designed to block the effects of proteins involved in cancer cell development and growth. The Food and Drug Administration (FDA) approved it for treatment of metastatic medullary thyroid cancer. Because of its mechanism of action, it is potentially active in other cancer types. Currently, there are Phase III trials recruiting for castration-resistant prostate cancer and metastatic renal cell carcinoma (which are expected to produce data in mid-2014), as well as a planned Phase III trial with hepatocellular carcinoma. Numerous Phase II studies are underway for a range of cancers, including prostate, ovarian, brain, melanoma, glioblastoma, breast, non-small cell lung, pancreatic, liver, and kidney.
I was unable to find any published studies of this drug for kidney cancer, and the trials in this disease are only getting under the way. There is, therefore, no basis on which to recommend this drug for renal cell carcinoma
Cometriq, Prescribing Information, 2014
NCCN.org, kidney cancer 2014